scholarly journals Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects

2015 ◽  
Vol 5 (3) ◽  
pp. 208-215 ◽  
Author(s):  
Herbert Struemper ◽  
Thomas Murtaugh ◽  
Jane Gilbert ◽  
Matthew E. Barton ◽  
Joseph Fire ◽  
...  
Keyword(s):  
Single Dose ◽  
Healthy Subjects ◽  
Relative Bioavailability ◽  
Prefilled Syringe

scholarly journals A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Jim Bush ◽  
Kazuki Kawakami ◽  
Rafael Muniz
Keyword(s):  
Healthy Subjects ◽  
Safety Concern ◽  
Relative Bioavailability ◽  
Open Label ◽  
Single Dose Study ◽  
Prefilled Syringe ◽  
Concentration Time ◽  
Disposable Syringe ◽  
Dose Study ◽  
Auto Injector

Abstract Background/objective FKB327 is a biosimilar of the adalimumab reference product (RP). The primary objective was to assess the relative bioavailability of FKB327 after a single subcutaneous (SC) dose via prefilled syringe (PFS), auto-injector (AI), or vial with a disposable syringe (vial), in healthy subjects. Methods This randomized, open-label, parallel-group, single SC-dose study was conducted in 195 healthy male and female subjects who were randomized 1:1:1 to receive FKB327 40 mg via PFS, AI, or vial. The primary pharmacokinetic (PK) parameters, areas under the serum concentration-time curve to the last detectable value (AUC0-t) and extrapolated to infinity (AUC0-∞), and maximum concentration (Cmax), were compared. Relative bioavailability was established if the ratio of geometric least squares (LS) means of the test product was within the predefined bioequivalence (BE) range of 0.80 to 1.25 of the RP for each comparison. Safety and immunogenicity were assessed. Results The mean serum FKB327 concentration-time profiles appeared similar across all 3 presentations. AUC0-t, AUC0-∞, and Cmax were within the predefined BE range for PFS compared with vial, suggesting comparable bioavailability. AUC0-∞ and Cmax of AI compared with vial and PFS were fully contained within BE range, although the upper limit of 90% confidence intervals of the geometric LS means ratios for AUC0-t was slightly high. Treatment-emergent adverse events in all 3 groups were mild, with no new safety concern with FKB327 identified. Similar immunogenicity was observed among administrations. Conclusion Among all 3 delivery methods, PK characteristics, safety profiles, and immunogenicity were similar. Trial registration EU Clinical Trials Registry EudraCTN2014–004469-26, registered October 14, 2014.

Sign in / Sign up

Export Citation Format

Share Document